The Utah Jazz are back to the grind on Tuesday night, facing off against the Memphis Grizzlies for their fifth of a six-game home stint.

Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.

X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of ...

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

Plus: JetBlue CEO eyes more growth in Boston; AG Andrea Campbell offers fiery words about Trump; Charles River chamber offers ...

The biotech company plans to move into the new development in 2028, consolidating other leased and owned spaces in the ...

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development ...

Through this agreement, Allarity will monitor potential trading abuses, detect unusual short-selling patterns, and ...

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025ORX750 Phase 2a ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

AlphaQuest LLC reduced its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 35.9% in the ...